Subscribe: MedWorm: Amyloidosis
http://www.medworm.com/rss/medicalfeeds/conditions/Amyloidosis.xml
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
amyloid  amyloidosis  cardiac amyloidosis  cardiac  disease  drug  medical  medworm message  medworm  new  news  source  study  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: MedWorm: Amyloidosis

MedWorm: Amyloidosis News



MedWorm.com provides a medical RSS filtering service. Thousands of medical RSS feeds are combined and output via different filters. This feed contains the latest news in Amyloidosis



Last Build Date: Thu, 15 Feb 2018 11:27:04 +0100

 



Case: Breast Amyloidosis Detected With 3D Mammography Case: Breast Amyloidosis Detected With 3D Mammography

Tue, 06 Feb 2018 05:14:48 +0100

Review the imaging characteristics of breast amyloidosis in this unusual case. How should definitive diagnosis be made?Applied Radiology (Source: Medscape Today Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis

Thu, 01 Feb 2018 03:02:14 +0100

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application... (Source: Drugs.com - New Drug Applications)



Alnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis

Tue, 12 Dec 2017 04:11:13 +0100

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 12, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and... (Source: Drugs.com - New Drug Applications)



U.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy

Mon, 20 Nov 2017 04:11:42 +0100

CAMBRIDGE, Mass.--(BUSINESS WIRE) November 20, 2017 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation... (Source: Drugs.com - New Drug Applications)



Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis

Thu, 16 Nov 2017 04:11:13 +0100

CAMBRIDGE, Mass.--(BUSINESS WIRE) November 16, 2017 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the company has initiated submission of a rolling New Drug Application (NDA) to the U.S. Food... (Source: Drugs.com - New Drug Applications)



Alnylam shares hit all-time high as rare disease drug continues to impress

Thu, 02 Nov 2017 17:42:31 +0100

Alnylam Pharmaceuticals added more than $1.5 billion to its market cap on Thursday after unveiling new data from a closely watched trial of its lead rare disease drug, which appeared to outperform a competitor ’s drug targeting the same disorder. Alnylam (Nasdaq: ALNY) reported new details from a Phase 3 trial of patisiran, a potential treatment for a disease called amyloidosis ­that affects around 10,000 people. The company previously said in September that the study had met all of its goals,… (Source: bizjournals.com Health Care:Biotechnology headlines)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Inotersen Shows Efficacy in Hereditary ATTR Inotersen Shows Efficacy in Hereditary ATTR

Fri, 20 Oct 2017 17:43:32 +0100

Improvements in neurologic and quality-of-life endpoints were seen in patients with hereditary transthyretin amyloidosis with polyneuropathy by using the investigational drug inotersen; side effects were called'monitorable. 'Medscape Medical News (Source: Medscape Medical News Headlines)



BU researcher receives NIH award to better understand wild-type transthyretin amyloidosis

Mon, 16 Oct 2017 04:00:00 +0100

(Boston University School of Medicine) Lawreen H. Connors, PhD, associate professor of pathology and laboratory medicine and biochemistry at Boston University School of Medicine (BUSM), is the recipient of a National Institutes of Health (NIH) High Priority, Short-Term Project Award, for her research 'molecular mechanism of senile cardiac amyloidosis.' (Source: EurekAlert! - Medicine and Health)



Experimental Alnylam drug hits mark in late-stage study, lifting shares

Wed, 20 Sep 2017 12:38:53 +0100

Alnylam Pharmaceuticals said Wednesday that its lead experimental drug for a rare disease had passed a late-stage trial, adding more than $1.5 billion to the Cambridge company ’s market cap in pre-market trading and potentially paving the way for a first-of-its-kind treatment to hit the market. Alnylam (Nasdaq: ALNY) said that the Phase 3 study of patisiran, which targets a disease called amyloidosis ­that affects around 10,000 people, had met all of its goals. Import antly, the company and its… (Source: bizjournals.com Health Care:Biotechnology headlines)



Distal Bicep Tendon Rip Tied to Transthyretin Amyloidosis

Wed, 13 Sep 2017 00:00:00 +0100

Findings in patients with heart failure with preserved ejection fraction (Source: Pulmonary Medicine News - Doctors Lounge)



Faster diagnosis of inherited and lethal nerve disease could advance search for new treatments

Tue, 11 Jul 2017 04:00:00 +0100

(Johns Hopkins Medicine) Johns Hopkins physicians report success in a small study of a modified skin biopsy that hastens the earlier diagnosis of an inherited and progressively fatal nerve disease and seems to offer a clearer view of the disorder's severity and progression. With a quicker and less invasive way to visualize the hallmark protein clumps of the rare but lethal disease -- familial transthyretin amyloidosis -- the researchers say they hope to more rapidly advance clinical trials of treatments that may slow the disease and extend patients' lives. (Source: EurekAlert! - Medicine and Health)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




X-Rays Of The Earliest Stage Of Alzheimer's Offer Critical Clue About How It Starts

Mon, 27 Mar 2017 09:01:02 +0100

This reporting is brought to you by HuffPost’s health and science platform, The Scope. Like us on Facebook and Twitter and tell us your story: scopestories@huffingtonpost.com. Sarah DiGiulio is The Huffington Post’s sleep reporter. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. (Source: Healthy Living - The Huffington Post)



Discovery's Edge: Cell research on amyloidosis

Tue, 21 Mar 2017 00:00:00 +0100

At Mayo Clinic, Marina Ramirez-Alvarado, Ph.D., studies one type of protein abnormality associated with a complex and incurable disease called light chain amyloidosis. This type of amyloidosis is the most common and can affect the heart, kidneys, skin, nerves, and liver.?Dr. Ramirez-Alvarado and her team just published a paper on their most recent findings in [...] (Source: News from Mayo Clinic)



New Options for Treating AL Amyloidosis

Thu, 23 Feb 2017 23:00:00 +0100

New treatment options are now available for light-chain amyloidosis, with additional ones on the way, according to a presentation at the 21st Annual International Congress on Hematologic Malignancies. (Source: CancerNetwork)



Circulating RBP4 IDs HF Caused by Transthyretin Amyloidosis (CME/CE)

Wed, 08 Feb 2017 18:22:47 +0100

(MedPage Today) --'Simple blood test'for underrecognized cause of heart failure (Source: MedPage Today Cardiovascular)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Engineering team finds compound may halt molecular cause of often-fatal condition

Mon, 06 Feb 2017 18:03:50 +0100

A team of engineers say a compound found in green tea could have lifesaving potential for patients with multiple myeloma and amyloidosis, who face often-fatal medical complications associated with bone-marrow disorders. (Source: ScienceDaily Headlines)



The power of tea

Mon, 06 Feb 2017 05:00:00 +0100

(Washington University in St. Louis) A team of engineers at Washington University in St. Louis and their German collaborators say a compound found in green tea could have lifesaving potential for patients with multiple myeloma and amyloidosis, who face often-fatal medical complications associated with bone-marrow disorders. (Source: EurekAlert! - Biology)



Amyloidosis Treatments Miss the Heart of the Problem

Wed, 07 Dec 2016 20:35:02 +0100

(MedPage Today) -- Only modest improvement in end organ function (Source: MedPage Today Nephrology)



With promising results from emerging therapies, research yields hope for amyloidosis

Thu, 01 Dec 2016 17:03:45 +0100

Two new treatments are showing promise and overall survival is on the rise for AL amyloidosis, according to a series of studies. Immunoglobulin light-chain amyloidosis (AL) is a rare, life-threatening disease that occurs when toxic proteins build up in organs, which alters their normal function. (Source: ScienceDaily Headlines)



With promising results from emerging therapies, Penn research yields hope for amyloidosis

Thu, 01 Dec 2016 05:00:00 +0100

(University of Pennsylvania School of Medicine) Two new treatments are showing promise and overall survival is on the rise for AL amyloidosis, according to a series of studies involving researchers in the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania. (Source: EurekAlert! - Cancer)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




[Research Article] De novo design of a biologically active amyloid

Thu, 10 Nov 2016 23:00:00 +0100

Most human proteins possess amyloidogenic segments, but only about 30 are associated with amyloid-associated pathologies, and it remains unclear what determines amyloid toxicity. We designed vascin, a synthetic amyloid peptide, based on an amyloidogenic fragment of vascular endothelial growth factor receptor 2 (VEGFR2), a protein that is not associated to amyloidosis. Vascin recapitulates key biophysical and biochemical characteristics of natural amyloids, penetrates cells, and seeds the aggregation of VEGFR2 through direct interaction. We found that amyloid toxicity is observed only in cells that both express VEGFR2 and are dependent on VEGFR2 activity for survival. Thus, amyloid toxicity here appears to be both protein-specific and conditional—determined by VEGFR2 loss of function in a...



JNM: Florbetaben-PET detects cardiac amyloidosis

Fri, 04 Nov 2016 07:00:00 +0100

Australian researchers have shown the proficiency of PET with the radiotracer...Read more on AuntMinnie.comRelated Reading: Piramal Imaging inks Taiwan deal Scintigraphy detects amyloid-related heart condition Florbetaben-PET finds more beta-amyloid plaques Florbetapir shows promise in detecting cardiac amyloid Study shows PiB-PET detects amyloid plaque in heart (Source: AuntMinnie.com Headlines)



PET imaging visualizes hard-to-diagnose cardiac amyloidosis

Tue, 01 Nov 2016 04:00:00 +0100

(Society of Nuclear Medicine) Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal deposits of proteins in the heart), which is notoriously difficult to diagnose, can be visualized noninvasively with positron emission tomography (PET) using the radiotracer fluorine-18 (F-18)-florbetaben. The study is published in the November issue of 'The Journal of Nuclear Medicine.' (Source: EurekAlert! - Medicine and Health)



Planar Cardiac Imaging Spots Transthyretin Cardiac Amyloidosis Planar Cardiac Imaging Spots Transthyretin Cardiac Amyloidosis

Fri, 02 Sep 2016 13:52:25 +0100

Technetium 99mpyrophosphate (Tc99mPYP) cardiac imaging effectively and noninvasively identifies transthyretin cardiac amyloidosis (ATTR-CA), according to findings from an observational study.Reuters Health Information (Source: Medscape Radiology Headlines)



DHA May Slow Cognitive Decline

Wed, 17 Aug 2016 16:20:06 +0100

There is a wealth of evidence that omega-3 fats such as DHA, found in salmon and other fish, play a role in both brain and heart health. In fact, infant formulas are supplemented with a type of DHA because it is critical to newborns' brain development. Now, a new study published in JAMA Neurology has shown an association between low levels of DHA and cerebral amyloidosis, a precursor of the beta-amyloid plaques common in the brains of people with Alzheimer's disease. The researchers took blood samples and conducted Amyvid PET scans of the brains of 61 seniors who did not show signs of cognitive impairment. (These scans, which were developed with early support from the Alzheimer's Drug Discovery Foundation, image beta-amyloid plaques in the brain.) They found that people with cerebral amy...

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Potential drug candidates could intervene in deadly diseases

Wed, 20 Jul 2016 20:48:25 +0100

Scientists have identified drug candidates that can boost a cell's ability to catch the 'typos' in protein production that can cause a deadly disease called amyloidosis, revealing a new approach to intervene in human disease. (Source: ScienceDaily Headlines)



TSRI team finds potential drug candidates that could intervene in deadly diseases

Wed, 20 Jul 2016 04:00:00 +0100

(Scripps Research Institute) In a new study, scientists at The Scripps Research Institute have identified drug candidates that can boost a cell's ability to catch the 'typos' in protein production that can cause a deadly disease called amyloidosis, revealing a new approach to intervene in human disease. (Source: EurekAlert! - Medicine and Health)



Bortezomib-Based Chemo Ups AL Cardiac Amyloidosis SurvivalBortezomib-Based Chemo Ups AL Cardiac Amyloidosis Survival

Wed, 29 Jun 2016 17:46:50 +0100

Heart failure due to light-chain amyloidosis is "one of the most devastating diagnoses a cardiologist may give a patient," one expert observes. Heartwire from Medscape (Source: Medscape Medical News Headlines)



Diabetes drugs may be useful for Alzheimer's, mice research finds

Wed, 22 Jun 2016 15:30:00 +0100

Conclusion Both Alzheimer's disease and diabetes seem to have become more common in recent years, causing illness and putting strain on the health service. News that the two illnesses may have a common cause raises hopes that drugs which help with one disease may also be of use in treating another. Trials of a diabetes drug on people with Alzheimer's disease are reported to be underway, although no results have been published yet. This study, suggesting a mechanism which may be involved in the early stages of both diseases, may increase the likelihood that common treatments will be useful. The study's main limitation is that it was carried out on mice, and studies in animals do not always translate directly to people. It's important to realise the study was not looking at ways to cure eith...



Calling All Researchers: Submit Your Grant Applications for the 2016 Brian D. Novis Research Awards

Fri, 27 May 2016 04:00:00 +0100

The Brian D. Novis Research Awards honor the IMF's founder Brian Novis, who died of multiple myeloma in July of 1992. The awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance), as well as immunoglobulin-derived amyloidosis. The 2016 awards are $50,000 each for junior grants and $80,000 for senior grants. August 1, 2016 is the deadline for applications. For more information and grant applications, click HERE. (Source: International Myeloma Foundation)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Amyloidosis

Thu, 19 May 2016 07:00:00 +0100

Title: AmyloidosisCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 5/19/2016 12:00:00 AM (Source: MedicineNet Arthritis General)



Sylvester researchers develop novel disease model to study multiple myeloma

Thu, 05 May 2016 04:00:00 +0100

(University of Miami Miller School of Medicine) Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed an animal model that allows them to better understand the mechanisms that lead to the development of multiple myeloma, a hematologic cancer of plasma cells, and the amyloidosis that sometimes accompanies it. (Source: EurekAlert! - Biology)



Protein trigger for juvenile idiopathic arthritis identified

Mon, 29 Feb 2016 00:00:00 +0100

US scientists have successfully identified a protein that plays a potentially key role in triggering juvenile idiopathic arthritis.Scientists at the Albert Einstein College of Medicine in New York have identified a human protein called transthyretin (TTR) that causes an autoimmune reaction in the joints of youngsters with this form of the disease - a discovery that could pave the way for new treatment options.The role of the TTR protein Juvenile idiopathic arthritis is the most common form of childhood arthritis and is understood to be an autoimmune disease, caused by antibodies attacking certain proteins in a person's own tissue.Prior to this study - published in the journal JCI Insight - no proteins triggering an immune attack had been associated with this particular disease. However...



Leading efforts to better understand amyloidosis diseases

Fri, 26 Feb 2016 14:00:00 +0100

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today. We’re pleased to host a guest blog from Isabelle Lousada, president and CEO of the Amyloidosis Research Consortium. (Source: The Catalyst)



Karmanos’ Myeloma and Amyloidosis team receives prestigious award for contributions to multiple myeloma research

Fri, 19 Feb 2016 21:51:04 +0100

(Source: Karmanos Cancer Institute)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.







Astrocytes implicated in preclinical AD

Sat, 13 Feb 2016 07:36:28 +0100

Astrocytes are activated in the brains of people with autosomal dominant Alzheimer’s disease long before symptoms appear and even before amyloidosis begins, a study shows. (Source: MedWire News)



Discovery: Molecular mechanism at root of familial amyloidosis and other diseases

Fri, 13 Nov 2015 13:00:00 +0100

A team of local researchers has proposed a molecular mechanism that may be responsible for the development of life-threatening diseases called amyloidoses. (Source: Parkinson's Disease News From Medical News Today)



Molecular mechanism at root of familial amyloidosis and other diseases

Thu, 12 Nov 2015 17:39:26 +0100

A team of local researchers has proposed a molecular mechanism that may be responsible for the development of life-threatening diseases called amyloidoses. The best known of such diseases is Alzheimer's disease, but there are many others that are receiving increased scrutiny, in part because of mounting evidence linking them to atherosclerosis and aging. (Source: ScienceDaily Headlines)



Predicting Progressive Atrophy in Mild Cognitive ImpairmentPredicting Progressive Atrophy in Mild Cognitive Impairment

Thu, 05 Nov 2015 15:24:40 +0100

Dr Barclay reviews a study aiming to determine how beta-amyloidosis and neurodegeneration predict regional progression of hypometabolism and atrophy in patients with mild cognitive impairment. Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.







High dose chemo & stem cell transplantation results in long-term survival for amyloid patients

Thu, 08 Oct 2015 04:00:00 +0100

(Boston University Medical Center) Patients with Light-chain amyloidosis who are treated with high-dose chemotherapy and autologous (one's own) stem cell transplantation (HDM/SCT) have the greatest success for long-term survival. (Source: EurekAlert! - Cancer)



Light Chain Amyloidosis No Systemic Threat (CME/CE)

Fri, 25 Sep 2015 18:30:00 +0100

(MedPage Today) -- Thorough initial evaluation, long-term follow-up essential (Source: MedPage Today Hematology/Oncology)



A Predictor of Early Cognitive Decline A Predictor of Early Cognitive Decline

Wed, 16 Sep 2015 18:34:04 +0100

A new study looks at the relationship between cerebral amyloidosis and cognitive decline in patients with autosomal dominant Alzheimer disease. Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)



Brain's Ability to Clear Amyloid Declines With AgeBrain's Ability to Clear Amyloid Declines With Age

Wed, 19 Aug 2015 19:50:26 +0100

The aging brain takes longer to clear amyloid-beta, a new study shows, which may explain why risk for the disease increases with age. It may also in the future allow risk prediction for Alzheimer's and amyloidosis. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Alnylam begins patisiran’s Apollo-Ole trial for ATTR amyloidosis

Mon, 20 Jul 2015 23:00:00 +0100

Alnylam Pharmaceuticals has started the Phase III open-label extension study (Apollo-Ole) with patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) to treat TTR-mediated amyloidosis (ATTR amyloidosis) in patients with familial… (Source: Drug Development Technology)



Two-Step Tx Shows Promise in Systemic Amyloidosis (CME/CE)

Wed, 15 Jul 2015 21:27:23 +0100

(MedPage Today) -- Significant declines in liver stiffness with an anti-amyloid monoclonal antibody. (Source: MedPage Today Gastroenterology)



Molecular Heart Imaging Could Spot Cardiac AmyloidosisMolecular Heart Imaging Could Spot Cardiac Amyloidosis

Tue, 09 Jun 2015 21:07:51 +0100

Myocardial scintigraphy with the bone radiotracer technetium-99m hydroxymethylene diphosphonate has prognostic value for patients with transthyretin-type amyloidosis, new research suggests. Medscape Medical News (Source: Medscape Medical News Headlines)



Localized Amyloidosis Carries Low Risk of Progression to Systemic DiseaseLocalized Amyloidosis Carries Low Risk of Progression to Systemic Disease

Tue, 26 May 2015 19:31:00 +0100

The prognosis for patients with localized amyloidosis appears to be good for long-term survival, but patients still need to be assessed and monitored for the more dangerous systemic amyloidosis, UK researchers report. Reuters Health Information (Source: Medscape FamilyMedicine Headlines)



Calling All Researchers: Submit Your Grant Applications for the 2016 Brian D. Novis Research Awards

Thu, 23 Apr 2015 04:00:00 +0100

The Brian D. Novis Research Awards honor the IMF's founder Brian Novis, who died of multiple myeloma in July of 1992. The awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance), as well as immunoglobulin derived amyloidosis. The 2016 awards are $50,000 each for junior grants and $80,000 for senior grants. August 3, 2015 is the deadline for applications. For more information and grant applications click HERE. (Source: International Myeloma Foundation)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Consumer Information on: Lixelle Beta 2-microglobulin Apheresis Column - H130001

Thu, 19 Mar 2015 04:00:00 +0100

The Lixelle Beta 2-microglobulin Apheresis Column (Lixelle Column) is a device that treats dialysis-related amyloidosis, a complication of kidney failure. The Lixelle Column contains specialized beads that remove a protein called Beta 2-microglobulin... (Source: Food and Drug Adminstration (FDA): CDRHNew)



FDA OKs First Device for Dialysis-Related AmyloidosisFDA OKs First Device for Dialysis-Related Amyloidosis

Wed, 11 Mar 2015 21:02:40 +0100

The authorization had a special humanitarian device exemption, used for a disease or condition that affects fewer than 4000 people in the United States each year. FDA Approvals (Source: Medscape Medical News Headlines)



UCLA study shows feasibility of blood-based test for diagnosing Alzheimer’s Disease

Wed, 11 Mar 2015 16:00:00 +0100

UCLA researchers have provided the first evidence that a simple blood test could be developed to confirm the presence of beta amyloid proteins in the brain, which is a hallmark of Alzheimer’s disease. Although approximately 5 million Americans are living with Alzheimer’s, no reliable blood-based test currently exists for the neurodegenerative disorder that is the sixth-leading cause of death in the United States. Using blood-based biomarkers — a signature of proteins in the blood that indicate the presence of a disease — to diagnose Alzheimer’s could be a key advance. “Blood-based biomarkers would have the important advantage of being safe, affordable and easy to administer in large groups or in rural areas, and therefore could have an enormous impact on clinical care and clini...



FDA Authorizes Use Of First Device To Treat Patients With Dialysis-Related Amyloidosis

Tue, 10 Mar 2015 02:11:03 +0100

The U.S. Food and Drug Administration recently authorized use of Lixelle Beta 2-microglobulin Apheresis Column, the first device to treat dialysis-related amyloidosis (DRA). (Source: Medical Design Online News)



First Device Approved for Dialysis-Related Amyloidosis

Mon, 09 Mar 2015 07:00:00 +0100

Title: First Device Approved for Dialysis-Related AmyloidosisCategory: Health NewsCreated: 3/6/2015 12:00:00 AMLast Editorial Review: 3/9/2015 12:00:00 AM (Source: MedicineNet Arthritis General)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




FDA authorizes use of first device to treat patients with dialysis-related amyloidosis

Fri, 06 Mar 2015 14:36:00 +0100

The U.S. Food and Drug Administration today authorized use of Lixelle Beta 2-microglobulin Apheresis Column, the first device to treat dialysis-related amyloidosis (DRA). (Source: Food and Drug Administration)



Amyloid formation may link Alzheimer disease and type 2 diabetes

Tue, 17 Feb 2015 13:37:41 +0100

The pathological process amyloidosis, in which misfolded proteins (amyloids) form insoluble fibril deposits, occurs in many diseases, including Alzheimer disease (AD) and type 2 diabetes mellitus (T2D). However, little is known about whether different forms of amyloid proteins interact or how amyloid formation begins in vivo. A new study has found evidence that amyloid from the brain can stimulate the growth of fibrils in the murine pancreas and pancreatic-related amyloid can be found along with brain-related amyloid in human brain senile plaques. (Source: ScienceDaily Headlines)



ASH: New Myeloma Regimens, AL Amyloidosis (CME/CE)

Mon, 15 Dec 2014 12:13:05 +0100

(MedPage Today) -- Add-on therapy with HDAC inhibitor improved outcomes in myeloma. (Source: MedPage Today State Required CME)



Prothena targets rare protein-misfolding disease in late-stage study

Tue, 02 Dec 2014 22:40:00 +0100

Elan Corp. spinout Prothena Corp. will take an experimental drug aimed at a rare protein-misfolding disease into a late-stage clinical trial, the company said Tuesday. Prothena (NASDAQ: PRTA), whose operations are largely based in South San Francisco, said it will focus its drug on amyloid light-chain amyloidosis, or AL amyloidosis, in what's expected to be a 230-patient, Phase III study. In the disease, misfolded amyloid proteins are deposited in tissue, causing progressive organ damage, including… (Source: bizjournals.com Health Care:Hospitals headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




MRI and LV Remodelling in Cardiac AmyloidosisMRI and LV Remodelling in Cardiac Amyloidosis

Thu, 20 Nov 2014 07:36:54 +0100

Learn more about the morphological features and remodelling patterns of cardiac amyloidosis as seen with cardiac magnetic resonance imaging. Heart (Source: Medscape Today Headlines)



Alnylam begins DISCOVERY trial to track TTR mutation prevalence

Wed, 24 Sep 2014 23:00:00 +0100

Alnylam Pharmaceuticals has started the DISCOVERY trial of its investigational candidate ALN-TTRsc, to evaluate the prevalence of transthyretin (TTR) mutations in patients suspected of cardiac amyloidosis. (Source: Drug Development Technology)



Hysterectomy Association Newsletter September 2014

Thu, 11 Sep 2014 17:47:03 +0100

Sourced from The Hysterectomy Association: Hysterectomy Association - Hysterectomy Association - hysterectomy, menopause and hormone replacement therapy (hrt) information and support for women. Welcome to the September newsletter. Well, my dire predictions of the summer ending thankfully didn’t come to anything and we seem to be enjoying a late summer bonus here in the UK. Hopefully that’s the case elsewhere in the world too. The Hysteria Writing Competition has finally closed to entries for this year and our judges are busy finishing off reading all the entries that arrived in the last week of August. When our winners have been announced I’ll let everyone know. Other News Items We’ve been asked to raise awareness of research into Amyloidosis to see if there is any...



Cardiac Amyloidosis: The Great ImitatorCardiac Amyloidosis: The Great Imitator

Mon, 08 Sep 2014 16:09:55 +0100

Three Mayo experts explain the three main types of cardiac amyloidosis and dispel some myths about the diagnosis and treatment of this rare condition. Mayo Clinic (Source: Medscape Cardiology Headlines)



Amyloidosis – Can you help relieve the pressure?

Tue, 02 Sep 2014 19:47:54 +0100

Sourced from The Hysterectomy Association: Hysterectomy Association - Hysterectomy Association - hysterectomy, menopause and hormone replacement therapy (hrt) information and support for women. Have you ever heard of amyloidosis? Don’t worry, I hadn’t either! The good news is you don’t have to be an expert on this rare and dangerous disease to help lighten the load of its victims. Amyloidosis is a condition which causes an excessive build-up of proteins in the blood. These proteins form clusters called ‘amyloids’, which are deposited around the sufferer’s body, putting undue pressure on the system where they land. Amyloids most often affect the body’s digestive system, central nervous system and the circulatory system. Needless to say, putting stress on these essential functi...

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Cajal-Retzius cell loss and amyloidosis in Alzheimer's disease

Mon, 05 May 2014 04:00:00 +0100

(Neural Regeneration Research) Cajal-Retzius cells are reelin-secreting neurons in the marginal zone of the neocortex and hippocampus. However, the relationship between Cajal-Retzius cells and Alzheimer's disease is unknown. (Source: EurekAlert! - Biology)



Widely-used anti-inflammatory drug shows success in treatment of amyloidosis

Mon, 30 Dec 2013 09:00:00 +0100

This study, published in the Dec. 25 issue of JAMA, is one of the first examples of successful repurposing of a generic drug to treat a rare disease. (Source: Health News from Medical News Today)



Alnylam starts Phase II study of ALN-TTRsc for treatment of TTR-mediated amyloidosis

Wed, 18 Dec 2013 12:00:00 +0100

US-based Alnylam Pharmaceuticals has started a pilot Phase II trial with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin (TTR) gene in development for the treatment of TTR-mediated amyloidosis (ATTR). (Source: Drug Development Technology)



Familial amyloidosis modeled in vitro using iPSC technology

Tue, 05 Nov 2013 08:00:00 +0100

Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have generated the first known disease-specific induced pluripotent stem cell (iPSC) lines from a patient with familial transthyretin amyloidosis (ATTR). The findings, which are reported in Stem Cell Reports, may lead to new treatments for genetic diseases such as familial amyloidosis. iPSCs are a form of stem cells that come from skin or blood cells reprogrammed into cells that have the ability to become any type of tissue in the body... (Source: Health News from Medical News Today)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Diagnosis: The Tell-Tale Green Heart

Fri, 01 Nov 2013 15:14:26 +0100

A very odd finding during routine surgery helps explain everything.     (Source: NYT Health)



Alnylam completes enrolment in Phase II Transthyretin-Mediated Amyloidosis clinical trial

Tue, 01 Oct 2013 23:00:00 +0100

Alnylam Pharmaceuticals has completed enrolment in its Phase II trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). (Source: Drug Development Technology)



Biomarker IDs Fibrotic Heart Failure (CME/CE)

Tue, 24 Sep 2013 15:16:34 +0100

ORLANDO (MedPage Today) -- Galectin-3 (Gal-3), a biomarker for fibrosis, may have a role in identifying heart failure caused by cardiac amyloidosis, researchers suggested. (Source: MedPage Today Cardiovascular)



Experimental Drug Shows Promise for Rare Genetic Disorder

Thu, 29 Aug 2013 20:19:43 +0100

New therapy may combat amyloidosis, the potentially deadly disease caused by protein build-up in organs (Source: WebMD Health)



Novel Approach to Amyloidosis Looks Promising (CME/CE)

Thu, 29 Aug 2013 19:13:00 +0100

(MedPage Today) -- An amyloidosis therapeutic strategy based on controlling gene expression passed a proof-of-concept test, suppressing transthyretin production in patients with transthyretin amyloidosis, investigators reported. (Source: MedPage Today Cardiovascular)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Experimental Drug Shows Promise for Rare Genetic Disorder

Thu, 29 Aug 2013 16:00:00 +0100

New therapy may combat amyloidosis, the potentially deadly disease caused by protein build-up in organs Source: HealthDay Related MedlinePlus Page: Amyloidosis (Source: MedlinePlus Health News)



Dreaming of animals and other warning signs of neurodegeneration | Mo Costandi

Wed, 22 May 2013 17:15:00 +0100

Sleep disturbances may be an early warning sign of Alzheimer's and other neurodegenerative diseasesThe latest issue of Nature contains an Outlook supplement about the health impacts of poor sleep, including a feature I wrote about the link between sleep disturbances and neurodegenerative diseases, called "Amyloid awakenings". The title refers to a process called amyloidosis, by which mutated, abnormally folded proteins aggregate to form insoluble clumps in the brain. Continue reading... (Source: Guardian Unlimited Science)



Prothena doses first patient in Phase I study of NEOD001

Tue, 23 Apr 2013 23:00:00 +0100

Clinical stage biotechnology company Prothena has dosed the first AL amyloidosis patient in its Phase I study of NEOD001, an antibody therapeutic candidate. (Source: Drug Development Technology)



Detecting Cardiac Amyloidosis Using Amyloid Imaging

Thu, 07 Feb 2013 08:00:00 +0100

While amyloid imaging may now be most associated with detecting plaques in the brain, it has the potential to change the way cardiac amyloidosis is diagnosed. According to first-of-its-kind research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) with 11C-PIB can positively visualize amyloid deposits in the heart. Currently there is no noninvasive test available for specific diagnosis. Cardiac amyloidosis is a deadly disorder caused by abnormal amyloid deposits in the heart tissue... (Source: Health News from Medical News Today)



Amyloid Imaging May Help Detect Cardiac Amyloidosis

Tue, 05 Feb 2013 08:30:04 +0100

Amyloid imaging, used to detect plaques in the brain, may help diagnose cardiac amyloidosis, researchers said. (Source: Diagnostic Imaging)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Amyloid imaging shows promise for detecting cardiac amyloidosis

Mon, 04 Feb 2013 16:42:42 +0100

While amyloid imaging may now be most associated with detecting plaques in the brain, it has the potential to change the way cardiac amyloidosis is diagnosed. According to first-of-its-kind research, positron emission tomography with 11C-PIB can positively visualize amyloid deposits in the heart. Currently there is no noninvasive test available for specific diagnosis. (Source: ScienceDaily Headlines)